- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07803146
Creative Processes and Children With a Neurodeveloppement Disorder (CREADEV)
September 2, 2026 updated by: Assistance Publique - Hôpitaux de Paris
Study of Creative Processes in Children Aged 6 to 12 With a Neurodeveloppement Disorder
Neurodevelopmental disorders (NDDs) are associated with diverse cognitive profiles, including creative abilities that remain poorly documented.
Studying creative processes in children helps to deepen our understanding of cognitive and developmental functioning in NDDs and to explore the development of more appropriate and inclusive assessment and support tools
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
Once consent has been obtained, the assessments are carried out within the Child and Adolescent Psychiatry Department at Robert-Debré Hospital.
The verbal and figural tests will be administered by a neuropsychologist or a trained doctor, following a standardised procedure:
- AUT (verbal)
- Ocsai-D
- LEGO building task
- Paediatric ICAA parent questionnaire
Study Type
Observational
Enrollment (Estimated)
212
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mylène FEFEU, MD
- Phone Number: 0033 0140032002
- Email: mylene.fefeu@aphp.fr
Study Locations
-
-
-
Paris, France, 75019
- Hôpital Robert Debré
-
Contact:
- Mylène FEFEU, MD
- Phone Number: 0033 0140032002
- Email: mylene.fefeu@aphp.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Children aged between 6 and 12 with a neurodevelopmental disorder, who are hospitalised in the ward.
Description
Inclusion Criteria:
- Children aged 6 to 12 years
- Prior inclusion in one of the existing clinical cohorts
- No objection from those with parental authority
- Consent from the participant, who must have read and understood the information leaflet
- No acute malnutrition or acute medical condition
Exclusion Criteria:
- Acute malnutrition or ongoing parenteral nutrition
- Acute intercurrent medical condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite creative Score
Time Frame: 5 years
|
To characterise performance in creativity and divergent thinking among patients with TND, using a range of stimuli
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
paediatric adaptation of the Inventory of Creative Activities and Achievement (ICAA).
Time Frame: A parent-completed questionnaire on children's creative achievements
|
At day 1
|
A parent-completed questionnaire on children's creative achievements
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Mylène FEFEU, MD, Assistance Publique - Hôpitaux de Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 15, 2026
Primary Completion (Estimated)
September 15, 2031
Study Completion (Estimated)
September 15, 2031
Study Registration Dates
First Submitted
August 28, 2026
First Submitted That Met QC Criteria
September 2, 2026
First Posted (Actual)
September 3, 2026
Study Record Updates
Last Update Posted (Actual)
September 3, 2026
Last Update Submitted That Met QC Criteria
September 2, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP260156
- 2026-A00346-45 (Other Identifier: ANSM- IDRCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.